RxDoctor Payments Data

Katerina Gradeva, APRN

Psychiatric/Mental Health · Boca Raton, FLNPI 1679291777

Payments from drug & device makers

$3,460in general payments, 2019–2025

Across 154 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$731
  • Supernus Pharmaceuticals, Inc.$398
  • Johnson & Johnson$343
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$310
  • Alkermes, Inc.$268
  • Neurocrine Biosciences, Inc.$238
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,460 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$27,994
Medicare patients
48
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole18$27,753
VraylarCariprazine Hcl20$24,486
TrintellixVortioxetine Hydrobromide15$13,928
LexaproEscitalopram Oxalate12$11,844
BelsomraSuvorexant25$10,639
Desvenlafaxine Succinate ErDesvenlafaxine Succinate88$4,152
Lurasidone Hcl54$2,940
Clonazepam293$1,994
Vilazodone Hcl17$1,805
Trazodone Hcl245$1,658
Quetiapine Fumarate128$1,043
Lamotrigine70$972
Bupropion XlBupropion Hcl100$945
Doxepin Hcl39$933
Mirtazapine79$925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Lexapro$731$36,33132 claims
Otsuka America Pharmaceutical, Inc.Rexulti$159$27,75318 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$90$13,92815 claims
MerckBelsomra$18$10,63925 claims
Almatica Pharma LLCSertraline Hcl$33$873209 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →